Efficacy of Ketoconazole in Hormone Refractory Prostate Cancer Patients

Authors

  • Parveen Shahida Akhtar Professor & Head, Department of Medical Oncology, NICRH, Mohakhali, Dhaka
  • Riaz Ahmed Chowdhury Associate Professor, Department of Surgery, Bangladesh Medical College, Dhaka
  • Jafar Md Masud Assistant Professor, Department Oncology, Bangladesh Medical College, Dhaka

DOI:

https://doi.org/10.3329/jom.v10i2.2814

Keywords:

Prostate cancer, hormone refractory prostate cancer, ketoconazole

Abstract

Prostate cancer is a common malignancy among males, with the incidence steadily rising over the past years. Patients with small volume metastasis where early chemotherapy is not warranted, in patients with biochemical failure, and in patients who refuse chemotherapy, management remains controversial as there is no universally accepted treatment protocol. Ketoconazole is an antimycotic that inhibits cytochrome P450 enzymes that are required for the synthesis of androgens and other steroids. In addition, in-vitro studies have suggested some direct cytotoxic effects in prostate cancer cell lines. This study aims to describe our experience with ketoconazole treatment for hormone refractory prostate cancer (HRPC) at our centre. Retrospective chart review of HRPC patients given ketoconazole at a private oncology centre in Dhaka from 2005 - 2006 was done. Patients had histologically proven adenocarcinoma of the prostate with rising Prostate Specific Antigen (PSA) despite androgen deprivation therapy (ADT) with orchiectomy, LHRH agonist therapy and antiandrogens. Ketoconazole was given at 200 mg thrice daily. A total of 10 patients with HRPC was treated and evaluated for response and toxicity. Median age was 70 years old.4 (40%) of the 10 patients had a greater than 50% decrease of PSA values. Responses were seen in 66.66% (2/3) of patients with bone-only disease, 20 % (1/5) of patients with bone and soft tissue disease and 1 patient with PSA-only disease. Median duration of response was 6.75 months (range 2-14 months).There were no grade 3 or 4 toxicities. Overall, 5 (50%) patients had toxicity related to ketoconazole. Its good toxicity profile, low cost and ease of administration makes it a viable option to this group of patients specially in our country.

Keyword: Prostate cancer, hormone refractory prostate cancer, ketoconazole  

doi: 10.3329/jom.v10i2.2814 J MEDICINE 2009; 10 : 52-55

Downloads

Download data is not yet available.
Abstract
115
PDF
236

Downloads

How to Cite

Akhtar, P. S., Chowdhury, R. A., & Masud, J. M. (2009). Efficacy of Ketoconazole in Hormone Refractory Prostate Cancer Patients. Journal of Medicine, 10(2), 52–55. https://doi.org/10.3329/jom.v10i2.2814

Issue

Vol. 10 No. 2 (2009)

Section

Original Articles

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).